Advertisement
MDAI vs NUWE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDAI is a StrongBuy and NUWE is a Buy.
MDAI's RSI Oscillator recovers from oversold territory
The RSI Indicator for MDAI moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on MDAI as a result. In 67 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for MDAI just turned positive on October 29, 2026. Looking at past instances where MDAI's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Following a +2.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDAI advanced for three days, in 136 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
MDAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 106 of 177 cases where MDAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 57 cases where MDAI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
MDAI moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MDAI crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.058) is normal, around the industry mean (4.209). P/E Ratio (-4.750) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.078) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. MDAI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NUWE's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NUWE turned positive on October 27, 2026. Looking at past instances where NUWE's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NUWE's RSI Oscillator exited the oversold zone, 49 of 61 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on NUWE as a result. In 68 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +6.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUWE advanced for three days, in 147 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NUWE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUWE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NUWE entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.004) is normal, around the industry mean (4.209). P/E Ratio (0.002) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.007) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. NUWE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUWE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NUWE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 93 | |
P/E GROWTH RATING 1..100 | 97 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MDAI | NUWE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 80% |
| Stochastic ODDS (%) | 4 days ago 49% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 63% | 4 days ago 83% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 88% |
| TrendWeek ODDS (%) | 4 days ago 60% | 4 days ago 78% |
| TrendMonth ODDS (%) | 4 days ago 67% | 4 days ago 90% |
| Advances ODDS (%) | 5 days ago 72% | 5 days ago 80% |
| Declines ODDS (%) | 11 days ago 78% | 11 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 71% | 4 days ago 86% |
| Aroon ODDS (%) | 4 days ago 60% | 4 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDAI’s FA Score shows that 1 FA rating(s) are green while NUWE’s FA Score has 1 green FA rating(s).
- MDAI’s FA Score: 1 green, 4 red.
- NUWE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDAI’s TA Score shows that 6 TA indicator(s) are bullish while NUWE’s TA Score has 5 bullish TA indicator(s).
- MDAI’s TA Score: 6 bullish, 4 bearish.
- NUWE’s TA Score: 5 bullish, 3 bearish.
Price Growth
MDAI (@Medical/Nursing Services) experienced а +6.25% price change this week, while NUWE (@Medical/Nursing Services) price change was +95.94% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.30%. For the same industry, the average monthly price growth was -8.32%, and the average quarterly price growth was -9.58%.
Reported Earning Dates
MDAI is expected to report earnings on Nov 10, 2026.
NUWE is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.30% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
MDAI and
Correlation & Price change
A.I.dvisor tells us that MDAI and OFIX have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MDAI and OFIX's prices will move in lockstep.
| Ticker / NAME | Correlation To MDAI | 1D Price Change % | ||
|---|---|---|---|---|
| MDAI | 100% | -2.55% | ||
| OFIX - MDAI | 33% Poorly correlated | -11.43% | ||
| MYO - MDAI | 27% Poorly correlated | -4.62% | ||
| PACB - MDAI | 27% Poorly correlated | -10.17% | ||
| MASS - MDAI | 26% Poorly correlated | -12.45% | ||
| BNGO - MDAI | 25% Poorly correlated | -4.17% | ||
More | ||||
NUWE and
Correlation & Price change
A.I.dvisor indicates that over the last year, NUWE has been loosely correlated with NYXH. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if NUWE jumps, then NYXH could also see price increases.
| Ticker / NAME | Correlation To NUWE | 1D Price Change % | ||
|---|---|---|---|---|
| NUWE | 100% | -1.73% | ||
| NYXH - NUWE | 33% Loosely correlated | -1.85% | ||
| CVRX - NUWE | 26% Poorly correlated | -1.05% | ||
| CERS - NUWE | 25% Poorly correlated | -6.56% | ||
| MDAI - NUWE | 25% Poorly correlated | -2.55% | ||
| PRE - NUWE | 24% Poorly correlated | -6.43% | ||
More | ||||